Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Hørsholm, Denmark, April 26, 2021 - ExpreS2ion Biotech Holding AB ("ExpreS2ion") hereby announces that Gitte L. Pedersen does not seek re-election to the Board of Directors at the forthcoming Annual General Meeting on May 26, 2021, and that two new members, Karin Garre and Sara Sande, are proposed for election. Thus, it is proposed to re-elect Jakob Knudsen, Martin Roland Jensen and Allan Rosetzsky and to elect Karin Garre and Sara Sande as new directors and to re-elect Martin Roland Jensen as chairman of the board.
Chairman of the Board Martin Roland Jensen comments
"I would like to take the opportunity to thank our board member Gitte who has been a valuable contribution to the company since being elected to the board in connection with our IPO in 2016. At the same time I welcome Karin and Sara who upon election joins the board with a wealth of experience that will complement the strategic direction of the company. This is an important step forward on ExpreS[2]ion's path to also become a pipeline and clinical development company alongside our important protein expression service providing business."
Biographies
Karin Garre
Dr. Karin Garre, born 1957, Danish citizen, is currently General Manager of Symphogen A/S, part of the SERVIER organization and member of the board of directors at Cervello A/S. Karin Garre has extensive leadership and drug development experience from +25 year in the pharmaceutical and biotech industries such as Astra A/S, Novo Nordisk A/S, Nycomed, Genmab and NeuroSearch, where she served in either line or corporate functions. Since 2004 in C-suite positions either as CDO, COO or CEO. Further, she brings experience from the Danish health care sector with recent five years as executive head of a Danish hospital site. Karin's key professional skills include overall leadership, strategy development and execution, change management processes and drug development from early to late stage phases and registration. Karin holds an MD from the University of Copenhagen (1983).
Sara Sande
Sara Sande, born 1975, Danish citizen, is currently Vice President, Global Commercial Development, CooperSurgical and member of the board of directors, Hydract A/S. Sara Sande has extensive leadership and top management experience from high-tech B2B companies (Vaekstfonden, IBM, KMD, Novozymes & CooperSurgical). Her key professional skills include sales leadership, strategy development, commercial excellence and business development. She has a deep understanding of what it takes to develop a successful commercial strategy and set up a world class commercial organization. Sara holds a Masters of Science in Economics (Cand. Polit.), Univrsity of Copenhagen (2002).
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se